35.172.217.174
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Conference Roundup

Brolucizumab interim treatment yields anatomic improvements

Interim treatment with brolucizumab in eyes with neovascular age-related macular degeneration (nAMD) after a suboptimal response to a fixed aflibercept, ranibizumab, or bevacizumab regimen resulted in anatomic improvements that were maintained for at least 6 months in a majority of eyes after switching back to the original anti-VEGF therapeutic, according...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-